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Sequence variability in surface-antigenic sites of pathogenic proteins is an important obstacle
in vaccine development. Over 200 distinct genomic sequences have been identified for
human papillomavirus (HPV), of which more than 18 are associated with cervical cancer.
Here, based on the high structural similarity of L1 surface loops within a group of phylo-
genetically close HPV types, we design a triple-type chimera of HPV33/58/52 using loop
swapping. The chimeric VLPs elicit neutralization titers comparable with a mix of the three
wild-type VLPs both in mice and non-human primates. This engineered region of the chimeric
protein recapitulates the conformational contours of the antigenic surfaces of the parental-
type proteins, offering a basis for this high immunity. Our stratagem is equally successful in
developing other triplet-type chimeras (HPV16/35/31, HPV56/66/53, HPV39/68/70,
HPV18/45/59), paving the way for the development of an improved HPV prophylactic
vaccine against all carcinogenic HPV strains. This technique may also be extrapolated to
other microbes.
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Vaccines are highly efficient weapons against infectiousdisease. However, multiple antigenic types or subtypesderived from the evolution of pathogenic microbes
through sequence variation presents a serious obstacle in vaccine
development. One way to tackle this variation is to include more
antigenic variants into a single vaccine, as exemplified with the
Streptococcus pneumoniae vaccine1 and Human papillomavirus
(HPV) prophylactic vaccine2. Yet, because pathogens, such as the
influenza viruses and human immunodeficiency virus (HIV),
have very high levels of antigenic variability, this approach is
fraught with difficulties, as an increase in type coverage will
dramatically enhance protein amount and adjuvant level per dose,
as well as increase the manufacturing complexity and associated
production costs. Studies that focus on designing immunogens
capable of inducing a broader protection against multiple sub-
types or variants require technical methods, such as computa-
tionally optimized broadly reactive antigen (COBRA)3, which
uses the consensus sequence from multiple variants to increase
the immunogenicity of the conserved epitopes that are shared
between subtypes and targeted by broadly neutralizing antibodies
among subtypes4–6. As yet, however, few studies have been suc-
cessful, and there is thus an urgent need to identify or design
antigens that can elicit antibodies with high and broad anti-virus
potency.
Oncogenic HPV infection is associated with several malig-
nancies, including cervical and anogenital cancer7. To date, more
than 200 distinct HPV genotypes have been identified, of which at
least 18 belong to the “high-risk” group and are chiefly respon-
sible for the development of cancer8–10. HPVs are non-enveloped,
double-stranded DNA viruses comprising multiple copies of the
major (L1) and minor (L2) capsid proteins. The native T= 7
HPV virion can be mimicked by an empty icosahedral shell,
called a virus-like particle (VLP) which consists of 72 L1-only
pentamers11,12. High-level neutralizing antibodies elicited by L1
VLPs can block HPV infection; however, protection against HPV
infection is type-restricted, and there tends to be little cross-
reactivity among HPV types13–15. Pre-clinical and clinical data
show that vaccinated patients exhibit low titers of neutralizing
antibodies against genetically related, non-vaccine HPV types in
highly reactive immune sera, and these antibodies may drop
below protective levels sooner than type-specific ones16–18. For
these reasons, the current market-available prophylactic HPV
vaccines: Cervarix19, Gardasil20 and Gardasil 9 are multivalent
vaccines of the various HPV L1 proteins. For example, Gardasil 9
provides type-specific protection against infection from nine
HPV types (HPV6, -11, 16, -18, -31, -33, -45, -52 and -58), the
last seven of which are responsible for about 90% of cervical
cancers.
The evolutionary history of HPV indicates a slow rate of HPV
mutation21; however, it is possible that genetic mutation and
recombination between different viruses may result in vaccine
evasion; for example, a recombination event between HPV16 and
HPV31 may result in a virus carrying HPV16 oncogenes but
coding for HPV31 structural proteins21. Indeed, previous work
shows that substitution of just a few residues on the FG loops of
L1 proteins between HPV16 and HPV31 can create a new ser-
otype, which would avoid the immunity conferred by both
types22. Furthermore, it remains unclear whether widespread
immunization with vaccines like Gardasil 9 would lead to an
increase in infection rates from the other carcinogenic HPV types
that are responsible for the remaining 10% of cervical cancer.
Ideally, an even broader vaccine that could protect against these
other types would help to avoid such concerns. However, the high
dosage already required for Gardasil 9 (270 μg protein in a single
dose) presents a significant challenge for the development of such
a broad-acting vaccine through standard manufacturing practices.
Previous studies on HPV structures have shown that the HPV
L1 monomer forms a canonical, eight-stranded β-barrel (BIDG-
CHEF), and both biochemical22–27 and structural analyses28–30
indicate that HPV type-specificity is largely dependent on five
highly variable surface loops—BC, DE, EF, FG and HI—on the
HPV capsid31,32. It stands to reason that a chimeric recombinant
L1 capsid comprising the antigenic determinants of different
HPV types may present an alternative strategy for the develop-
ment of a cross-type or wide-spectrum HPV vaccine. Previous
reports have observed that the recognition region (i.e., homo-
logous sequences on the surface loops) of type-specific neu-
tralizing antibodies of one HPV type (type A) could be
transferred to create a chimeric VLP of another type
(type B)23,33–35. However, previous studies show that such a
chimeric VLP of type B only generated low levels of neutralizing
antibodies that could cross-react with type A22,34, and because of
this poor response, there was little further interest in developing
chimeric L1 VLPs based on such epitope grafting.
In this study, we sought to develop a highly efficacious, cross-
type vaccine candidate against the infection of two or more HPV
types using an epitope grafting approach. We initially found that
the L1 proteins of various HPV types shared an overall conserved
structure in their core regions and even in their basic surface loop
configurations, with phenotype variations between different HPV
types able to be induced by minor structural movements of the
surface loops. Our design is based on a rational understanding of
the high structural conservation of L1 surface loops within phy-
logenetically close HPV types despite sequence variation; and we
used this knowledge to select among hundreds of HPV variants to
engineer chimeric particles. Here we characterized a chimeric
HPV cross-type vaccine candidate with comparable efficacy to
that of mixed wild-type (WT) VLPs. Our study confirms that the
strict type specificity of HPV can be undermined by the intro-
duction of a few residue substitutions between genetically close
HPV types, introducing an appealing strategy for the design and
development of wider-spectrum vaccines against HPV as well as
other pathogenic microbes.
Results
Genetically close HPV types share high structural similarity.
The type-specific neutralization epitopes of HPV, which are
located on the surface of the HPV capsid, are mostly mediated by
the pentamers36. To ascertain whether structural divergence drives
HPV type specificity, we scrutinized the crystal structures of L1
pentamers of genetically close or distant HPV types (Fig. 1a, b).
First, L1 proteins of HPV33 and HPV52 were cloned and
expressed in E.coli, purified, digested by trypsin, and crystalized.
The crystal structures of HPV33 and HPV52 pentamers were
determined to resolutions of 2.9Å and 2.75Å, respectively (Table 1,
Supplementary Fig. 1a), with refinement to Rwork/Rfree values of
21.0/24.0% and 18.7/23.5%, respectively. Both structures show a
hollow lumen in the central axis, and two neighboring monomers
intertwined by surface loops (Fig. 1b, Supplementary Fig. 1a).
Each L1 monomer folds into a canonical, eight-stranded β-barrel
(BIDG-CHEF), with the strands joined via flexible surface loops
(BC, DE, EF, FG, HI; Supplementary Fig. 1b, c). The same sec-
ondary structural elemental profile is found among various
L1 structures (HPV11/16/18/35/58/59)12,31.
Next, we sought to determine the extent of the differences in
the tertiary structures of L1 proteins among different HPV types;
these are well defined in the electron density map, even for the
variable loops located on the outer surface (Supplementary Fig. 2).
It should be noted that the surface loops in the non-
crystallographic symmetry (NCS)-related monomers within the
asymmetric unit of HPV33, HPV52, and HPV58 might differ
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Fig. 1 Phylogenetic classification among the major capsid proteins (L1) of multiple types, and a structural comparison of HPV L1s. a Phylogenetic tree of
HPV L1 proteins based on the amino acid sequences of 20 HPV types. The bar at the bottom provides a scale for the change in evolutionary lineages over
time. Twenty HPV types were divided into seven groups based on evolutionary distance of their L1 proteins: Group 1 (blue): HPV33, -52 and -58; Group 2
(cyan): HPV16, -31 and -35; Group 3 (purple): HPV53, -56 and -66; Group 4 (yellow): HPV26, -51 and -69; Group 5 (orange): HPV39, -68 and -70; Group 6
(pink): HPV18, -45 and -59; and Group 7 (green): HPV6 and -11. b Structural comparison of loop structure among HPV types of HPV33, -58 (PDB code:
5Y9E), -52, -18 (PDB code: 2R5I), and -59 (PDB code: 5J6R). The loops are colored by type: HPV33 (light blue), HPV58 (deep blue), HPV52 (marine),
HPV18 (light pink) and HPV59 (red). The loop sequence alignments among types are shown above the corresponding loop structure, with residue
differences compared with HPV58 colored red
Table 1 Data collection and refinement statistics
HPV33 HPV52 H58-33BC H58-33BC-52HI
Data collection
Space group P21 C2 P21 P1
Cell dimensions
a, b, c (Å) 98.8, 171.9, 145.7 306.8, 105.1, 196.9 153.7, 105.8, 154.7 136.5, 209.8, 212.6
α, β, γ (°) 90.0, 97.0, 90.0 90.0, 125.8, 90.0 90.0, 99.5, 90.0 60.5, 85.1, 90.1
Resolution (Å) 50.0–2.9 (2.97–2.92)a,b 50.0–2.7 (2.80–2.75) 50.0–2.5 (2.54–2.50) 50.0–3.5 (3.56–3.50)
Rsym (%) 9.5 (75.1) 19.9 (123.8) 13.4 (83.3) 17.1 (64.5)
I / σI 14.2 (2.1) 12.1 (1.8) 11.1 (1.8) 4.8 (1.3)
Completeness (%) 99.8 (99.9) 99.9 (100.0) 99.8 (99.7) 97.0 (87.2)
Redundancy 3.7 (3.7) 7.6 (7.6) 3.7 (3.7) 1.9 (1.8)
Refinement
Resolution (Å) 48.2–2.9 42.7–2.8 40.8–2.5 40.4–3.5
No. reflections 105,166 131,736 169,776 248,099
Rwork / Rfree 21.0/24.0 18.7/23.5 18.2/21.6 31.5/34.0
No. atoms 33,033 33,256 34,661 133,168
Protein 33,033 33,256 33,241 133,168
Water — — 1420 —
B-factors 76.1 53.0 40.7 105.5
Protein 76.1 53.0 40.9 105.5
Water — — 35.0 —
R.m.s. deviations
Bond lengths (Å) 0.003 0.007 0.004 0.003
Bond angles (°) 0.65 0.93 0.67 0.62
aOne crystal was used for each structure.
bValues in parentheses are for highest-resolution shell
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slightly in conformation due to their intrinsic flexibilities
(Supplementary Fig. 3). First, we divided 20 of the major HPV
types into seven groups based on evolutionary distance of L1
proteins: 18 of these are responsible for more than 99% of cervical
cancer, with HPV6 and 11, in particular, accountable for about
90% of genital warts (Fig. 1a, Supplementary Table 1). Then, five
L1 pentamer structures representing two groups (group 1:
HPV58, -33 and -52; group 6: HPV18 and -59) were aligned to
compare the structural differences among their five surface loops.
We show that the overall loop structures are conserved for all five
surface loops among various types of L1 structures. Nevertheless,
the variable sequence identity of individual genotypes induces
small loop movements between types, as shown in the super-
imposed structures. We also observe that the surface loops of
types within group 1 or group 6 have quite similar main-chain
traces, with minor differences noted among the loops between the
two groups. The extent of loop movement between L1s are
correlated with aa sequence diversity in terms of residue type and
sequence length (Fig. 1b). Furthermore, pairwise structural
comparisons were carried out between NCS copies of L1
monomers from five HPV types and the mean root mean
squared deviations (RMSDs) were generated for both the core
regions and the surface loops of L1 for the various genotypes
(Supplementary Table 2). In the comprehensive structural
comparisons, both the core region structures and the surface
variable regions—constituted by five surface loops among the
various types of L1 structures—shared conserved structural
configurations, with RMSD values of Cα ranging from 0.22 to
0.59Å and from 0.53 to 2.06Å, respectively (Supplementary
Table 2). The minor loop movements, particularly between types
from group 1 and group 6 (Fig. 1b), slightly increased the RMSD
values with respect to that of the relatively rigid core region,
which was believed to be associated with the various type-specific
phenotype variations underlying virus phylogenetic evolution.
Collectively, the structural information suggests high conserva-
tion of the overall structures of L1 within a phylogenetic group of
HPV, which even extends across different groups, despite minor
variations in the outer antigenic surface loops.
Design and expression of chimeric HPV VLPs. Viral epitopes
that induce neutralizing antibodies against HPV seem to cover
more than one surface loop on a single L1 protein25,28,29,37,38; this
may explain why high variability in the loop region leads to type
specificity among different HPV genotypes. Therefore, our ana-
lysis on the structure of HPV33/58/52/18/59 types demonstrated
that the L1 surface loops showed high structural similarities
within a phylogenetic group, which remarkably extended across
different groups, with only minor variation in the antigenic loops.
This type of conserved structure despite genotypic evolution
illustrates the variability that can be induced while conserving
function, and then provides preliminary structural information to
explain the cross-protection achieved by HPV vaccines against
infection with a limited number of phylogenetically related HPV
types39,40. We thus propose that highly potent cross-type pro-
tection against HPV infection could be achieved by creating a
chimeric HPV VLP that contains antigenic determinants from
genetically close HPV types in same phylogenetic group rather
than evolutionarily distant HPV types across groups. Given the
extent of the structural diversity among the five surface loops, it is
assumed that comprehensive loop swapping trials could be
implemented to screen for an appropriate chimera that may
confer the expected cross-type antigenicity and immunogenicity.
To test our hypothesis, we genetically swapped the loop
sequences on five surface regions (BC/DE/EF/FG/HI) between the
two most phylogenetically related HPV types—HPV33 and
HPV58—and generated 10 chimeric L1 constructs: H33-58BC,
H33-58DE, H33-58EF, H33-58FG, H33-58HI, H58-33BC, H58-
33DE, H58-33EF, H58-33FG and H58-33HI (Fig. 2a and
Supplementary Fig. 4). These mutants were expressed in E.coli
(Supplementary Fig. 5a, b), and self-assembly of the purified
mutated L1 proteins was confirmed by transmission electron
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Fig. 2Molecular design and antigenic characterization of loop-swapped HPV33/58 chimeric VLPs. a Schematic representation of the wild types (WTs) and
the chimeric HPV33/58 L1 proteins. The location of surface loops for each WT or mutated L1 protein are labeled by amino acid position. b Heatmap
representations of the EC50 values of chimeric HPV33/58 VLPs based on ELISA assays against a type-specific mAb panel of HPV33 and HPV58 VLPs. The
key indicates the heatmap gradient. A detailed characterization of each mAb is shown in Supplementary Table 3
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microscopy (Supplementary Fig. 5c). Particle size and homo-
geneity of the chimeric HPV VLPs, as determined by high-
performance size-exclusion chromatography (HPSEC) and ana-
lytical ultra-centrifugation (AUC), were similar to those measures
observed for WT L1 VLPs of their corresponding backbone type
(Supplementary Fig. 5c). Using differential scanning calorimetry
(DSC), we found that the transition corresponding to the melting
temperature (Tm) in the DSC trace occurred at 77.28 °C for WT
HPV33 VLPs and 68.61 °C for WT HPV58 VLPs, whereas the
Tm values for the chimeric HPV33 VLPs (H33-58BC, H33-58DE,
H33-58EF, H33-58FG and H33-58HI) and chimeric HPV58
VLPs (H58-33BC, H58-33DE, H58-33EF, H58-33FG and H58-
33HI) ranged from 61 to 74 °C and 62 to 67 °C, respectively.
These results indicated no obvious effects on the structural
stabilities of the L1 VLPs following the amino acids substitutions
on the capsid surface regions (Supplementary Fig. 5).
Antigenicity and immunogenicity of chimeric HPV33/58
VLPs. To investigate the antigenicity of the chimeric HPV33/58
VLPs, we employed a panel of neutralizing antibodies against
HPV33 and HPV58 (Supplementary Table 3); this allowed us to
evaluate the binding ability of the VLP mutants to those type-
specific antibodies. The median effective concentrations (EC50) of
the mAb panel to various chimeric HPV33/58 VLPs was deter-
mined by ELISA assay (Fig. 2b). We observed the following three
main findings: (1) The binding of HPV33 (or HPV58) mAbs was
affected, to varying degrees, by loop substitutions at one of
the five surface loops (Fig. 2b), suggesting that particular loop(s)
are responsible for mAb recognition. Notably, five of the nine
HPV33-specific mAbs (C2C3, C14A2, C16D7, 9A3 and 7A3)
failed to bind to the BC loop-swapped mutant of HPV33 (H33-
58BC), suggesting that the BC loop of HPV33 may involve a
major neutralization epitope. (2) Enhanced binding activity of
multiple non-backbone-type mAbs to chimeric VLPs was found
following the substitution of several amino acids on different
surface loops of HPV58 into HPV33 (and vice versa). Specially,
eight HPV58-specific mAbs showed binding to the DE loop-
swapped mutant of HPV33 (H33-58DE; Fig. 2b and Supple-
mentary Table. 3). (3) Binding of several mAbs to WT VLPs
could be disrupted by single loop substitutions with the hetero-
logous type; i.e., replacement of one of the four loops (BC, DE, EF
and FG) in WT HPV33 VLP abrogated the binding of the specific
mAb 9A3, suggesting that these four loops are involved in mAb
9A3 recognition of HPV33 VLP.
To assess the immunogenicity of the cross-type chimeric HPV33/
58 VLPs, BALB/c mice were inoculated three times with chimeric
VLPs formulated with aluminum adjuvant. The neutralization titers
of the sera were measured with a pseudo-virion–based cell
neutralization assay. We noticed that the WT HPV33 and
HPV58 VLPs can elicit moderate reciprocal cross-type neutraliza-
tion titers ranging from 101.2 to 102.6, which is consistent with
previous results41. Meanwhile, all of the chimeric HPV33/58 VLPs
showed improved heterotypic antibody responses, and this occurred
without changing the elicitation of neutralization antibodies against
their own backbone types (Fig. 3a). Notably, the anti-HPV58
antibody titers of H33-58DE and H33-58HI were 25-fold (titers
ranging from 10,000 to 102,400; P < 0.01) and 80-fold (102,400 to
212,400; P < 0.001) higher than that found in mice immunized with
WT HPV33 VLPs (2.5 to 102,400), respectively (Fig. 3a), whereas
H58-33BC, H58-33DE, and H58-33HI could induce, respectively,
325-fold (24,000 to 204,800; P < 0.001), 94-fold (2,000 to 51,200;
P < 0.01), and 52-fold (1,700 to 33,000; P < 0.01) higher titers
against PsV33 than that elicited by WT HPV58 VLPs (Fig. 3a).
H33-58HI and H58-33BC mutants showed comparable cross-
protection potency as that conferred by bivalent HPV33 and
HPV58 VLPs against both HPV33 and HPV58 (Fig. 3a).
Therefore, these two mutants were subjected to further study,
testing immunogenicity assays in mice. We found that immuni-
zation with higher concentrations per dose led to higher titers:
animals receiving 0.1 μg per dose of chimeric VLP H33-58HI and
H58-33BC were capable of inducing anti-HPV58 and anti-
HPV33 neutralization titers of up to 49,500 and 29,000,
respectively (Fig. 3b); 1 μg per dose led to 1.5-fold
(50,000–92,000) and 3.3-fold (64,000–126,000) higher neutraliza-
tion titers, respectively, than with 0.1 μg per dose; and 10 μg per
dose led to 2.0-fold (102,000–192,000) and 1.5-fold
(100,000–195,000) higher neutralization titers, respectively, than
with 0.1 μg per dose. These results were reflected by the ED50
values of the chimeric VLPs; the ED50 values define the minimum
effective dose that provides seroconversion in 50% of the animals
in a given group42. As shown in Table 2 and Supplementary
Table 4, the ED50 values of H33-58HI were as low as 0.053 μg for
HPV33 and 0.049 μg for HPV58, whereas, for H58-33BC, the
values were 0.043 μg and 0.019 μg, respectively. This indicates
that VLPs of both H33-58HI and H58-33BC could provide cross
protection against HPV33 and HPV58 at levels comparable with
that of WT HPV58 and HPV33, respectively (Table 2).
Furthermore, we questioned whether the cross protection
afforded by these two chimeras was achieved by multiple
simultaneous mutations. We generated eight single mutation
chimeras of HPV33 VLPs (mutated to the HPV58 HI loop: H33-
S350K, H33-D351E, H33-S352G, H33-E357D) and HPV58 VLPs
(mutated to the HPV33 BC loop: H58-S80N, H58-N82T, H58-
N84A, H58-V87L). The neutralization titers of the anti-sera of
these chimeras were measured and we found that most of the
single-point mutants (except for H58-V87L) could elicit hetero-
typic neutralization antibodies (Supplementary Fig. 6) to some
extent; this indicated that every residue associated with type-
restricted neutralization contributes to the cross-neutralization
when substituted to the other type. Intriguingly, the H33-E357D
chimera was able to induce a cross-type neutralization titer as
high as that of H33-58HI (Supplementary Fig. 6), possibly
demonstrating that residue D377 of HPV58 L1 takes a critical
role during the immune recognition process of HPV58.
To check if cross-protection could be achieved by introducing
mutations from more distantly related HPV types, we generated
two chimeric VLPs—H33-59HI and H58-59BC—using the
distant type HPV59, which belongs to another group in the
phylogenetic tree (Fig. 1a; Supplementary Fig. 7a, b). To evaluate
their potential cross-type immunogenicity, mice were immunized
three times with a higher dose (100 μg) of proteins absorbed with
a stronger Freund’s adjuvant (Supplementary Fig. 7c). In contrast
to the high neutralization titers against heterologous types elicited
by H33-58HI and H58-33BC, we found no increase in the anti-
HPV59 antibody response in the antisera of either H33-59HI or
H58-59BC (Supplementary Fig. 7c). Thus, cross-protective
immunities was not be elicited by proteins engineered using
genetically distant types.
Immunogenicity of triple-type HPV33/58/52 chimeras. To
explore the feasibility of including more genetically close geno-
types into a single, chimeric L1 VLP type, HPV52—which is
closest to both HPV33 and HPV58 (Fig. 1a)—was engineered
into the lead HPV33/58 chimeric VLPs, H33-58HI and H58-
33BC, by individually swapping each of the remaining four loops
with those from HPV52. This resulted in eight HPV33/58/52
chimeras: H33-58HI-52BC, H33-58HI-52DE, H33-58HI-52EF,
H33-58HI-52FG, H58-33BC-52DE, H58-33BC-52EF, H58-33BC-
52FG and H58-33BC-52HI (Fig. 4 and Supplementary Fig. 8a–c).
The VLPs from these chimeras were then used to immunize mice
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to assess their cross-type immunogenicity. Of the eight triple-type
chimeric VLPs, H33-58HI-52DE and H33-58HI-52FG showed
the highest anti-HPV52 antibody titers (4700–2200 and
1300–47900, respectively; P < 0.001) as compared with the H33-
58HI control. H58-33BC-52DE and H58-33BC-52HI also
showed high titers (2,280–23,440 and 2,180–87,430, respectively;
P < 0.001) as compared with the H58-33BC control (Fig. 4b). No
anti-HPV52 neutralizing antibodies were found for any of the
controls (WT HPV33, WT HPV58, or HPV33/58 chimeras).
Intriguingly, two of the triple chimeras—H33-58HI-52FG and
H58-33BC-52FG—showed lower anti-HPV58 neutralizing titers
than those of their backbone VLPs (30-fold [1,700–10,640] and
330-fold [2.5–5,400] for H33-58HI and H58-33BC, respectively);
this suggested that the FG loop (in HPV58 in particular) was part
of the immunodominant region associated with the neutralizing
antibody production. Anti-HPV33 neutralization titers for all
triple chimeras remained comparable with that of their parental
double chimeras.
Next, we further measured the anti-HPV52 immunogenicity of
four selected candidates—H33-58HI-52DE, H33-58HI-52FG,
H58-33BC-52DE and H58-33BC-52HI—using three different
immunization doses (0.1, 1 and 10 μg), as before. All four
mutants showed dose-dependent anti-HPV52 neutralization
antibody responses (Fig. 5a). However, H33-58HI-52FG, which
showed moderate antibody titers (2,280–23,440) in the cross-type
immunogenicity assays, failed to show high potency against
Table 2 Half-effective dosage (ED50) of double-type and
triple-type chimeras in mice
Antigen
category
HPV VLP ED50 (μg)
anti-
HPV33
anti-
HPV58
anti-
HPV52
Wild-type
control
HPV33 0.066a > 0.3 —
HPV58 > 0.3 0.006 —
Double-type
chimera
H33-58HI 0.053 0.049 —
H58-33BC 0.043 0.019 —
Wild-type
control
HPV33 0.013b >0.3 >0.3
HPV58 > 0.3 0.021 >0.3
HPV52 >0.3 >0.3 0.046
H33&58&52 0.009 0.009 0.017
Triple-type
chimera
H33-58HI-52DE 0.083 0.069 0.557
H33-58HI-52FG 0.046 0.243 0.087
H58-33BC-52DE 0.009 0.014 0.341
H58-33BC-52HI 0.065 0.058 0.041
aRefer to the detailed ED50 calculation in Supplementary Table 4
bRefer to the detailed ED50 calculation in Supplementary Table 5
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HPV52 infection in groups receiving doses as low as 0.1 μg or 1
μg (Fig. 5a, left and middle). Also, the ED50 values for these four
chimeras were measured to test their immunogenicity against
infection of all three HPV types. Overall, only H58-33BC-52HI
conferred high immune efficacy against infections from all three
genotypes (HPV33 [ED50, 0.065 μg], HPV52 [0.041 μg] and
HPV58 [0.058 μg]), reaching comparable levels to those provided
by a mix of the WT VLPs of HPV33, -52, and -58 (0.009 μg,
0.017 μg, and 0.009 μg, respectively; Table 2 and Supplementary
Table 5).
Immunogenicity of other chimeric VLP combinations. To test
whether this method could be applied to produce other triple
HPV types, we attempted to graft immunodominant epitopes into
a single L1 molecule within different groups. Four chimeras
(H35-16FG-31BC, H66-56HI-53FG, H39-68FG-70HI and H45-
18BC-59HI) were generated for Groups 2, -3, -5 and -6 (Fig. 1a)
based on the protocol summarized for the generation of HPV58-
33BC-52HI, and were tested in mice (5 μg per dose). All four
chimeric VLPs showed high cross-protective efficacy for each
group (Fig. 5b and Supplementary Fig. 9), with at least 150-fold
increased heterotypic neutralization titer achieved by these lead
candidates as compared with the backbone type, without sig-
nificantly affecting the original immunization response (Supple-
mentary Table 6). Thus, we believe that engineering in the surface
loops between closely related HPV types can be used to optimally
modulate the immunodominance among different types.
Immunogenicity and immune durability in non-human pri-
mates. We next immunized cynomolgus macaques (Macaca
Fascicularis) with the lead HPV33/58/52 vaccine candidate to
evaluate vaccine-induced immunity. Monkeys (n= 4 per group)
were administered with 5 μg of the H58-33BC-52HI chimeric
VLPs formulated with aluminum adjuvant at week 0 and 8.
Neutralization titers were measured from antisera drawn at week
10. Immunization with WT HPV VLPs resulted in minor cross-
neutralization of HPV33 and HPV58 in monkeys (titers ranging
from 50 to 500); however, no cross-reactive antibodies to HPV52
were observed with HPV33 or HPV58 WT VLPs, and similarly,
no cross-reactive antibodies to HPV33 or HPV58 were detectable
after HPV52 VLP immunization (Fig. 6a). Nevertheless, the
cross-reactive antibody titers for HPV33 were significantly (26-
fold) higher with the chimeric VLPs (960 to 6,290, P < 0.001;
Fig. 4a, left) than with the HPV58 WT VLPs; reciprocally, the
anti-HPV58 antibody titer (6,060 to 40,960) of H58-33BC-52HI
was also 54-fold higher than that of HPV33 WT VLPs (P < 0.001;
Fig. 6a, right). The chimeric VLPs could also elicit a mean neu-
tralization titer of 5,400 (1,780 to 8,460) against HPV52 (Fig. 6a,
middle). Thus, engineered loop swapping can produce high
immune potency and provide cross-type protection of phylo-
genetically related HPV types.
We then tested the kinetics of the vaccine-induced neutralizing
antibodies in immunized monkeys. Two weeks after the first
vaccination, the anti-HPV33 neutralizing titer reached ~200, with
the titers then slightly decreasing until the second immunization
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Fig. 4 Immunogenicity of loop-swapped HPV33/58/52 chimeric VLPs. a Schematic representation of the chimeric HPV33/52/58 L1 proteins based on
chimeric L1 proteins H33-58HI and H58-33BC. A group of mice were immunized with mixed WT HPV33, -52 and -58 VLPs. b Neutralization titers of the
immune sera from BALB/c mice (n= 4) collected 4 weeks after the third immunization (immunization at weeks 0, 2 and 4 with 5 μg per dose of aluminum
adjuvant-containing tripe-type chimeric or WT VLPs). All the data were analyzed by one-way ANOVA, **P < 0.01; ***P < 0.001; ****P < 0.0001. The error
bars are standard deviation and symbols represent individual mice. The dotted line indicates the limit of detection for the assay. Non-neutralizing sera were
assigned a value of one-half of the limit of detection for visualization
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at week 8 (Fig. 6b, left). Titer levels peaked at four weeks after the
second vaccination (week 12), slightly decreasing over time but
remaining high even after four and a half months (~2,200 at week
26); albeit, this titer was ~2-fold lower than that of mixed WT
VLPs of HPV33/52/58 (Fig. 6b, left). Similar kinetic curves were
observed for anti-HPV52 (Fig. 6b, middle) and anti-HPV58
neutralizing titers (Fig. 6b, right), with the overall titer against
HPV52 and HPV58 reaching 1,100 and 22,000 at week 26,
respectively (Fig. 6b). Neutralizing antibody titers in monkeys
immunized with WT HPV33 or WT HPV58 VLPs showed
increased reciprocal neutralization after the first and second
vaccinations but these also reduced over time, with low cross-
protective antibody titers of ~25 (anti-HPV58) for HPV33 and
~33 (anti-HPV33) for HPV58 by week 26 (Fig. 6b, left and right).
In monkeys receiving HPV52 VLPs, no cross-reactive antibodies
were found for either HPV33 or HPV58 at week 26 (Fig. 6b, left
and right), as anticipated. Overall, the data confirm the high
immune potency and cross-type protection afforded by the
HPV33/52/58 chimeric VLPs designed through the exchange of
several amino acids between phylogenetically close related types
(Fig. 7a and Supplementary Fig. 10), and also indicate that
antibody production can be enhanced in pre-existing immunity
and immunization with these chimeric VLPs to provide long-
lasting (~4.5 months) protection, at levels comparable with that
achieved by mixing three WT HPV VLPs at three times the
dosage (versus one dose with the chimeric VLPs; Fig. 6b).
Structures of chimeric pentamers and VLPs-Fab complexes.
We solved the crystal structures of pentamers of the lead double
and triple chimeric candidates H58-33BC and H58-33BC-52HI to
resolutions of 2.5Å and 3.5Å, respectively (Fig. 7b and Supple-
mentary Fig. 11a; Table 1). The two pentamer structures of the
chimeric mutants were superimposed against wild-type structures
of HPV58, 33 and 52 to identify marked structural differences
(Fig. 7b-d). Consistent with the high structural similarities within
this phylogenetic group, as indicated in Fig. 1, the type-specific aa
replacement in both the BC loop and HI loop still did not sub-
stantially change the main-chain conformation of these two loops
in the chimeras (Fig 7c, d top left). Further pairwise comparisons
of the surface contours of wild types and mutants illustrated that
the most distinct bumpy protrusions between parental and
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targeting types were located on the side-chains of K53H33,
N57H33, K59H33 and K60H33 for HPV58 vs. HPV33 (Fig. 7c,
bottom left), and K380H52, S383H52 and E388H52 for HPV58 vs.
HPV52 (Fig. 7d, bottom left). By loop swapping with a few aa
mutations on HPV58 L1—i.e., S80N, N82T, N84A and V87L for
BC loop, T375K, G378S and D383E for HI loop (Fig. 7a)—the
resurfaced structural contours of the BC and HI loops of the
chimera nearly recapitulate those of the HPV33 BC loop (Fig. 7c,
middle and right) and HPV52 HI loop (Fig. 7d, right), respec-
tively. These subtle structural resurfacing changes in the engi-
neered regions might provide structural evidence for the cross-
protective immunity of the chimeric proteins.
To verify that the residues exchanged on the surface loops of
HPV58 introduce a similar functional surface area as that of the
corresponding heterologous type, we recruited mAb 4E5—a
conformational and type-specific neutralizing antibody of
HPV33, the binding of which could be redirected to H58-33BC
and H52-33BC-52HI (Figs 2b, 8a, c, d, Supplementary Fig. 12 and
Supplementary Table 7)—and determined cryoEM structures of
the 4E5 Fab in complex with HPV33 WT VLPs (HPV33:4E5) and
both chimeric VLPs (H58-33BC:4E5 and H58-33BC-52HI:4E5).
The cryo-EM structures of HPV33:4E5, H58-33BC:4E5 and H58-
33BC-52HI:4E5 were reconstructed to 12.3Å, 12.0Å and 10.0Å,
respectively (Fig. 8d, Supplementary Fig. 13; Supplementary
Table 8). From the cryoEM micrographs and 2D class averages,
we can discern obvious protrusions, which we consider as the
bound 4E5 Fabs, for both chimeric VLPs:4E5 complexes, similar
to that observed for the HPV33:4E5 complex (Supplementary
Figs. 13a, 14). The HPV33:4E5 complex map shows strong
density corresponding to five bound 4E5 Fabs around the
periphery of the upper rim of the 5-coordinated pentamer of the
capsid; although, much lower and discontinuous densities for the
4E5 Fabs bound to 6-coordinated pentamer were also observed
(Fig. 8d, left), which could be mainly caused by steric hindrance
among bound Fabs30. Analysis of the extracted cryoEM map of
one 5-coordinated HPV33 pentamer and one 4E5 Fab revealed
that the 4E5 Fab is bound to the outer rim of the HPV33
capsomer at an angle of ~58° to the pentamer surface
(Supplementary Fig. 13c). Similar binding occupancies and
binding angles (60° for H58-33BC:4E5 and 60° for H58-33BC-
52HI:4E5) were observed for 4E5 Fabs bound to L1 monomers of
both H58-33BC:4E5 and H58-33BC-52HI:4E5 complexes (Fig. 8d,
middle and right, and Supplementary Fig. 13c, middle and right).
This suggests that the same recognition mode was adopted by
mAb 4E5 to the VLPs of HPV33 and the chimeric HPV58/33 and
HPV58/33/52. Further analysis of the mapped epitopes suggests
that the 4E5 Fab binding orientation and footprints covering both
the BC loop and the EF loop are similar for all three VLPs-Fab
complexes (Fig. 8e and Supplementary Fig. 13d). These data
provide strong evidence that loop swapping of the BC loop from
HPV33 onto the HPV58 basal framework can mimic the
molecular surface of HPV33 and give rise to heterotypic
neutralizing antibodies in vivo.
Discussion
Genetic mutation and recombination are routinely used by
pathogens to avoid host immune system recognition, particularly
in surface-exposed regions which are targeted by the immune
machinery; this also happens to be where most of the neutralizing
epitopes are located. The immunodominant epitopes of
HPV pathogens usually involve multiple surface regions that
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are discontinuous in the primary sequence, so that type
specificity persists even following one or a few amino acids
substitutions22–27,34. Based on our immunogenicity assays in
mice and non-human privates, we have successfully generated
triple-type chimeric HPV proteins that can simultaneously pre-
sent three independent immunodominant epitopes, using seven
or fewer amino acid substitutions. We believe that our success is
borne from an understanding of the structural and ancestral
relationships among multiple HPV types, and, thereafter, the
selection of closely related types for epitope grafting.
Our data show that different loops have variable effects on
transferring cross-protection between different groups (Figs 4, 5);
this could be primarily caused by their inconsistent antigenic
determinants for type specificity. Still, additional structural
information of the chimeric VLPs needs to be considered to
rationalize how to select particular loops for chimeras with high
cross-protective efficacy. We also noticed that, among the five
surface loops, there is no EF loop-exchange constructs for any of
the lead triple-type candidates among the five groups (Group-1,
-2, 3, -5 and -6) (Fig. 5), even though an increased heterotypic
neutralization could be observed in EF loop-swapped constructs;
i.e., the anti-HPV58 antibody titer of H33-58EF was ~2- to 3-log
higher than that found following immunization with WT HPV33
VLPs (Fig. 3a). One possible explanation is that the EF loop is
not a major component in determining HPV type-specificity.
Alternatively, it is possible that the higher flexibility displayed on
the EF loop than the other loops makes it more difficult to
provide a similar heterotypic functional area through EF loop
exchange.
Although the chimeric HPV VLPs had similar physical prop-
erties to that of WT VLPs (Supplementary Figs. 8, 9), the chimeric
VLPs provide a major increment in HPV protection by inducing
efficient neutralizing antibodies against a broad spectrum of HPV,
with five chimeric VLPs able to induce immunity against a total of
15 HPV types in mice presented in our study. Even though evo-
lutionary changes tend to be slow in papillomavirus43,44, recom-
bination events between different types of viruses may lead to
vaccine evasion; for example, as mentioned earlier, recombination
events between HPV16 and HPV31 can result in a virus carrying
HPV16 oncogenes but coding for HPV31 structural proteins or a
completely new serotype21. Therefore, a cross-type HPV vaccine
with a much broader spectrum against similar types could become
an alternative means to provide potential protection against the
effects of mutation events and/or infection of parental types not
included in current vaccines. We propose that, with necessary
modifications, an improved HPV vaccine could be engineered to
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elicit protective immunity against 20 types of HPV through seven
chimeric VLPs, along with carcinogenic HPV types from group 4,
and other low-risk types (e.g., HPV6 and HPV11, which are not
associated with cervical cancer, but are linked with precancerous or
dysplastic lesions and genital warts) (Fig. 1a). This would
hypothetically cover more than 99% of HPV infection that cause
cervical cancers45.
Increasing the immunity of conserved neutralizing epitopes
offers a logical strategy for the design of broadly protective
immunogens; this would be based on a molecular understanding
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subjected to reducing SDS-PAGE and western blot (WB) analysis with mAb 4E5. mAb 4B3, a linear antibody capable of recognizing HPV L1 protein, was
employed as a positive control for the WB experiment. c Affinity constants of the chimeric mutants (H58-33BC and H58-33BC-52HI) and WT VLPs
(HPV33, HPV52 and HPV58) against mAb 4E5 were measured by surface plasma resonance (SPR) in a Biacore 3000. The error bars are standard
deviation of experiments performed in triplicate. d CryoEM structures of the VLPs-Fab complexes of HPV33:4E5 (left), H58-33BC:4E5 (middle) and H58-
33BC-52HI:4E5 (right). Density maps are colored by radius from cyan (230 Å), to yellow (280 Å), to pink (320 Å). Icosahedral 2-, 3- and 5-fold axes are
indicated by black symbols. For the purpose of comparability, the cryoEM maps at higher resolution were low-pass filtered to 12.3 Å. e Close-up view of the
roadmaps of HPV33:4E5 (left), HPV58-33BC:4E5 (middle) and HPV58-33BC-52HI (right) surfaces, projected by an area surrounding a 5-fold vertex
defined with a polar angle θ range of 46° to 58° and a polar angle ϕ range of 68°–86°. Color scheme for surface residues are according to surface loops
(BC, amber; DE, orange; EF, yellow; FG, green and HI, Cyan). Blue contour lines were drawn according to the projection of the Fab-4E5 entity with a density
greater than 1 and within a radial section of the VLP-4E5 complex ranging from 310 Å to 360 Å. The icosahedral symmetry axes are labeled. The roadmaps
were generated by the software RIVEM68
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of the interactions between isolated broadly neutralizing anti-
bodies and protective antigens4. However, no immunogen to date
has successfully elicited antibodies with high potent cross-type
neutralizing ability, probably due to the limited information
available about the conserved regions of natural antigens or the
poor immunogenicity of the conserved areas, since such regions
appear to be generally inaccessible in the pathogen’s native state.
Here, we provide a rational approach for structure-based cross-
type vaccine design: (1) Structure similarity (where the structure
is available) and evolutionary distance analyses were performed to
define type groups that could be incorporated into one chimera;
(2) Chimeric loop-substituted mutants created between two most
closely related types were initially generated to determine can-
didate(s) that would elicit an ideal double-type immunization
response; constructs where swapping occurred between more
structurally similar loops were prioritized, as only limited con-
structs could be generated and assayed for immunogenicity; (3)
The remaining four loops of the double-type candidate(s) were
then independently exchanged to the corresponding loop of a
third genetically close type, and immunogenicity was evaluated to
achieve the optimal triple-type chimeric VLPs; again, constructs
where swapping had occurred on more structurally similar loops
were prioritized. Although HPV sequence diversity is not as high
as that of RNA viruses, such as the human immunodeficiency and
influenza viruses, or single-stranded DNA viruses, with extensive
structural information, the method provided here still could
markedly benefit the development of a new generation of vaccines
for a wide variety of pathogens.
Methods
Protein cloning, expression and purification. N-terminally truncated HPV16
(GenBank: ANA05496 [https://www.ncbi.nlm.nih.gov/protein/ANA05496]),
HPV18 (AAQ92369 [https://www.ncbi.nlm.nih.gov/protein/AAQ92369]), HPV31
(P17388, [https://www.ncbi.nlm.nih.gov/protein/P17388]), HPV33 (AMY16565,
[https://www.ncbi.nlm.nih.gov/protein/AMY16565]), HPV35 (P27232, [https://
www.ncbi.nlm.nih.gov/protein/P27232]), HPV39 (P24838, [https://www.ncbi.nlm.
nih.gov/protein/P24838]), HPV45 (P36741, [https://www.ncbi.nlm.nih.gov/
protein/P36741]), HPV52 (AML80965, [https://www.ncbi.nlm.nih.gov/protein/
AML80965]), HPV53 (NP_041848, [https://www.ncbi.nlm.nih.gov/protein/
NP_041848]), HPV56 (P36743, [https://www.ncbi.nlm.nih.gov/protein/P36743]),
HPV58 (AFS33402, [https://www.ncbi.nlm.nih.gov/protein/AFS33402]), HPV59
(CAA54856, [https://www.ncbi.nlm.nih.gov/protein/CAA54856]), HPV66
(ABO76893, [https://www.ncbi.nlm.nih.gov/protein/ABO76893]), HPV68
(AGU90787, [https://www.ncbi.nlm.nih.gov/protein/AGU90787]) and HPV70
(P50793, [https://www.ncbi.nlm.nih.gov/protein/P50793]) L1 genes were cloned
into pTO-T7 vector. Mutations were constructed using Gibson assembly46, a
potent reconstitution polymerase chain reaction (PCR) strategy. Briefly, two gene
fragments from their templates were cloned by specific primers (Refer to the pri-
mer list in Supplementary Data 1). Gibson assembly was then used to construct the
targeted clone with these two fragments as templates. All recombinant HPV L1
proteins were produced in ER2566 E. coli strain as described previously12. Briefly,
the E. coli strain containing L1 expression vectors was induced with 0.4 mM iso-
propyl-β-D-thiogalactopyranoside for 10 h at 25 °C. The harvested cells were re-
suspended in buffer (50 mM Tris-HCl, pH 7.2, 10 mM EDTA, 300 mM NaCl) and
disrupted by sonication. The supernatant was purified by two chromatography
procedures using SP sepharose (GE Healthcare, America) and CHT II resin (Bio-
Rad, America). For VLP preparation, the purified L1 proteins were dialyzed with
the above-mentioned buffer without reductant to allow VLP self-assembly; To
prepare pentamers for crystallization, the Cys175 (as numbered according to the
sequence of HPV16 L1) in L1 proteins was replaced with Ser and the mutated
proteins were then subjected to limited trypsin digestion (mass ratio of trypsin vs.
L1 protein was approximately 1:1000) at room temperature overnight and purified
by Superdex 200.
Crystallization and structural determinations. Purified HPV L1 pentamers of
concentration at ~5 mgmL−1 were performed for crystallization trial in sitting-
drop vapor diffusion method in 96-well plates at 20 °C. Best crystals were grown by
mixing 1 µL sample with 1 µL reservoir solution using the hanging-drop vapor-
diffusion method in 24-well plates (Reservoir solutions: for HPV33 pentamer: 0.2
M magnesium formate, 13.5% (w/v) PEG 3350; for HPV52 pentamer: 8% tasimate,
17.5% (w/v) PEG 3350; for HPV58-33BC pentamer: 0.2 M potassium thiocyanate,
23% (w/v) PEG 3350; for HPV58-33BC-52HI pentamer: 0.2 M calcium acetate,
18% (w/v) PEG 3350). Crystals were cryo-protected in their respective reservoir
solutions supplemented with 30% glycerol, and flash-cooled at 100 K.Diffraction
data from the HPV33, HPV52, HPV58-33BC, HPV58-33BC-52HI L1 pentamer
crystals were collected at the Shanghai Synchrotron Radiation Facility beamline
BL17U using a Quantum-315r CCD Area Detector. All datasets were indexed,
integrated, scaled and merged using the HKL-2000 program package (http://www.
hkl-xray.com). The structures were solved by molecular replacement with PHA-
SER47. The crystal structure of HPV58 pentamer (PDB 5Y9E [http://dx.doi.org/
10.2210/pdb5Y9E/pdb]) served as the search model. The interest models were built
manually in Coot, refined by PHENIX48 and analyzed by MolProbity49 (96.3%
favored, 0.3% outliers for HPV33; 96.0% favored, 0.2% outliers for HPV52; 97.0%
favored, 0.2% outliers for H58-33BC; 95.4% favored, 0.2% outliers for H58-33BC-
52HI). Briefly, one round of rigid-body refinement was performed after molecular
replacement. Afterwards, the resulting models were manually corrected and refined
by COOT50. Coordinates and individual B factors of HPV52 and HPV58-33BC
pentamers were refined in reciprocal space without non-crystallographic symmetry
(NCS) restraints, whereas the coordinates and group B factors of HPV33 and
HPV58-33BC-52HI pentamers were refined in reciprocal space with NCS restraints
and secondary structure restraints to avoid overfitting. Data collection and struc-
ture refinement statistics are given in Table 1.
Sequence alignment and phylogenic tree construction. Multiple sequence
alignment of the L1 proteins from 20 different HPV types was conducted using
Clustal Omega51 and the phylogenic tree was constructed by the neighbor-joining
method using software MEGA 552 (http://www.megasoftware.net/). The tree was
drawn to scale, with branch lengths measured in the number of substitutions per
site. The five additional types of HPV L1 protein sequences downloaded from
GenBank (accession numbers: HPV6, AAC80442 [https://www.ncbi.nlm.nih.gov/
protein/AAC80442]; HPV11, P04012 [https://www.ncbi.nlm.nih.gov/protein/
P04012]; HPV26, NP_041787 [https://www.ncbi.nlm.nih.gov/protein/NP_041787];
HPV51, AJS10540 [https://www.ncbi.nlm.nih.gov/protein/AJS10540]; HPV69,
ALJ32828 [https://www.ncbi.nlm.nih.gov/protein/ALJ32828]) along with 15 types
of sequences as mentioned above were used for phylogenetic analysis.
SDS-PAGE and western blotting. SDS-PAGE was performed using the Laemmli
method with minor modifications53. Briefly, samples were diluted with Laemmli
sample buffer (0.0625M Tris-HCl, pH 6.8, 2% (w/v) SDS, 10% (w/v) glycerol,
100 mM dithiothreitol, and 0.001% (w/v) bromophenol blue) to a final protein
concentration of 1 mgmL−1 or 0.2 mg ml−1. Samples were heated to 80 °C for 10
min, loaded into the wells of 10% acrylamide gels, electrophoresed, and stained
with Coomassie Brilliant Blue.
For western blotting, resolved proteins were electrically transferred to
nitrocellulose membranes for 55 min at 35 mA. Membranes were blocked with 5%
skim milk, incubated with anti-HPV L1 linear mAb 4B3 (recognizing a broad-
spectrum linear epitope, 1:1000 dilution), washed, and then incubated with goat
anti-mouse alkaline phosphatase-conjugated antibody (Dako, Denmark). Color
was developed over 5 min using NBT/BCIP reagent (Pierce Biotechnology;
Rockford, IL).
Indirect ELISA. The wells of 96-well microplates were coated with wild type (WT)
or chimeric VLPs (300 ng per well) and then blocked overnight at 4 °C. The wells
were then incubated with two-fold serial dilutions of the antibody for 45min at
37 °C. Antibody titers were detected using a horseradish peroxidase (HRP)-con-
jugated goat anti-mouse IgG antibody (diluted 1:5000 in HS-PBS, Abcam; Cam-
bridge, UK), followed by 50 µL of 3, 3′, 5, 5′-Tetramethylbenzidine Liquid Substrate
(Sigma-Aldrich, St Louis, MO) per well for 15min at 37 °C. The reaction was
stopped by the addition of 50 μl of 2M H2SO4, and the absorbance read at 450 nm
(reference, 620 nm) using an automated ELISA reader (TECAN, Männedorf,
Switzerland). The median effective concentration (EC50, ng mL−1) is defined as the
antibody concentration for achieving 50% binding with the antigen. Data analysis
was performed using GraphPad Prism (GraphPad Software, San Diego, CA).
Analytical ultracentrifugation (AUC). The homogeneity and molecular mass of
HPV L1 proteins were determined using sedimentation velocity (SV) experiments.
SV was performed at 20 °C on a Beckman XL-A analytical ultracentrifuge,
equipped with absorbance optics and an An60-Ti rotor (Beckman Coulter; Full-
erton, CA). All the samples were diluted to an OD280nm of 1 in a 1.2-cm light path.
A total of 150 scans for samples were recorded and the rotor speed was set to 7,000
rpm for VLPs, and 30,000 r.p.m. for pentamers. The sedimentation coefficient was
obtained using the c(s) method with the Sedfit software54, kindly provided by Dr.
P. Schuck at the National Institutes of Health (Bethesda, MD).
High-performance size-exclusion chromatography (HPSEC). Purified WT or
chimeric HPV L1 VLPs were chromatographed using a 1120 Compact LC HPLC
system (Agilent Technologies; Santa Clara, CA) separately, equipped with a TSK
Gel PW5000xl 7.8 × 300 mm column (TOSOH, Japan); columns were pre-
equilibrated in phosphate buffer, pH 6.5 with 500 mM NaCl. The column flow rate
and protein signal detection for the SEC analysis were 0.5 ml/min and 280 nm,
respectively.
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Differential scanning calorimetry (DSC). DSC was performed on HPV L1 VLPs
using a MicroCal VP-DSC instrument (GE Healthcare, MicroCal Products Group;
Northampton, MA). Samples (0.5 mg mL−1) were measured at a heating rate of 1.5
°Cmin−1 using a scanning temperature that ranged from 10 °C to 90 °C. Software
MicroCal Origin 7.0 (Origin-Lab Corp., Northampton, MA) was used to calculate
the melting temperatures (Tm) based on the melting curves.
Monoclonal antibodies (mAbs). BALB/c mice were immunized subcutaneously
three times at 2-week intervals with HPV33 VLPs or HPV58 VLPs (100 μg per
mice) absorbed with aluminum adjuvant for prime immunization. Mice also
received two additional boost inoculations. Fusion was performed 2 weeks after the
final immunization. The resulting hybridomas were screened using indirect HPV33
or HPV58 VLP-based ELISA and pseudovirus-based neutralization assays (PBNA,
see below). Positive cells were cloned by limiting dilution at least three times until a
single cell clone was attained. MAbs were prepared by injecting hybridoma cells
into the peritoneal cavities of pristane-primed BALB/c mice; ascitic fluid was
collected after 9–12 days, and the mAbs were purified by Protein A affinity
chromatography. The purified anti-HPV33 mAbs (4E5, 7C12, 11A3, 11F4, C2C3,
C14A2, C16D7, 9A3 and 7A3) and anti-HPV58 mAbs (4A2, 13A4, 5H2, 10B11,
5G9, A15A9, A10B8, 1D4 and 3E4) were diluted to 1.0 mg ml−1 in PBS and stored
at −20 °C. mAb concentration was determined with a BCA method.
BIAcore biosensor analysis. CM-5 sensor chips were amine-coupled to a goat
anti-mouse antibody Fc fragment (GAM-Fc) (BIAcore 3000, GE). One flow cell of
a chip was coated with 15,000 RU (resonance units) of the GAM-Fc, whereas the
other flow cell was left uncoated and blocked as a control. The affinity measure-
ments of mAb 4E5 binding with HPV33, HPV58, HPV52, H58-33BC and H58-
33BC-52HI pentamer, respectively, were initiated by passing HBS (10 mM HEPES,
pH 7.4 and 150 mM NaCl) over the sensor surface for 100 s at 30 μl min−1, fol-
lowed by injection of 1 μg ml−1 of mAb 4E5 at 30 μl min−1 for 3.3 min, and then
injections of serially diluted antigens at 30 μLmin−1 for 3.3 min. Every measure-
ment on the BIAcore 3000 biosensor was performed three times and the individual
values were used to produce the mean affinity constant and standard deviation.
Preparation of HPV pseudoviruses. The L1/L2 expression vector and pN31-
EGFP used in the experiment were kindly provided by Dr. J. T. Schiller55. Briefly,
plasmids carrying codon-optimized HPV L1 genes were individually co-transfected
with an L2 expression plasmid and the marker plasmid into 293FT cells, which
were purchased from Thermo Fisher (Catalogue number: R70007) and had been
authenticated by Short Tandem Repeat (STR) assay and single nucleotide poly-
morphism (SNP) genotyping, and tested for the absence of mycoplasma con-
tamination. The cells were harvested 72 h after transfection, lysed with cell lysis
buffer containing 0.5% Brij58 (Sigma-Aldrich), 0.2% benzonase (Merck Millipore;
Darmstadt, Germany), 0.2% PlasmidSafe ATP-Dependent DNase (Epicenter Bio-
technologies, Madison, WI) and DPBS-Mg solution, and incubated at 37 °C for 24
h. Afterward, 5 M NaCl solution was added to the samples to extract the cell
lysates. The TCID50 (tissue culture infective dose) of the supernatant was then
measured to determine the titers of the PsVs, calculated according to the classical
Reed–Muench method56. Maturation and purification of these samples followed
the procedures described before57–59.
Pseudovirion-based neutralization assay (PBNA). 293FT cells were incubated at
37 °C in the wells of a 96-well plate at a density of 1.5 × 104 cells per well for 6 h.
Sera were 2-fold diluted and PsVs were diluted to 2 × 105 TCID50/µL. Equal
volumes (60 µl) of the PsV diluent and the serially diluted sera were mixed and
incubated at 4 °C for 1 h. The negative control was prepared by mixing 60 µL of the
PsV diluent with an equal volume of culture medium. Then, 100 µL of each
mixture was added to designated wells and incubated at 37 °C for 72 h. The neu-
tralization titers were calculated as the log10 of the highest sera dilution with a
percentile of infection inhibition higher than 50%. Every sample was repeated at
least three times, and the mean values and SD are reported.
Ethics statement. Animal experiments in mice were approved by Xiamen Uni-
versity Laboratory Animal Center (XMULAC). The immunization and serum
harvest of cynomolgus macaques were conducted at WuXi AppTec Co., Ltd.
(Suzhou, P. R. China) (Contract no. XMU-20160525A). The manipulation protocol
was approved by WuXi Institutional Animal Care and Use Committee (IACUC).
All procedures were conducted in accordance with animal ethics guidelines and
approved protocols to minimize suffering during vaccination, blood collection, and
euthanasia.
Animals, immunizations and serological analysis. To initially assess the
immunogenicity of all chimeric VLPs, special pathogen-free (SPF) BALB/c mice
(n= 4 or 5) were immunized intraperitoneally three times at an interval of 2 weeks
(weeks 0, 2 and 4) with chimeric or WT VLPs diluted in aluminum adjuvant (5 μg
per dose). Serum samples were collected at week 8, and the neutralizing titers were
analyzed by PBNA, as described above.
To verify cross protection of H33-59HI and H58-59BC chimeric VLPs, WT
VLPs and chimeric H33-58HI and H58-33BC VLPs (100 μg per dose), absorbed
with Freund’s adjuvant, were used to immunize SPF BALB/c mice (n= 3)
subcutaneously three times at an interval of 2 weeks (weeks 0, 2 and 4). Serum
samples were taken at week 8 after the first immunization to determine the
neutralizing titers by PBNA.
For dose-dependent response immunogenicity evaluations, SPF BALB/c mice
were immunized intraperitoneally three times with three different doses (0.1, 1 and
10 μg, n= 5 or 6 per dose) at an interval of 2 weeks (weeks 0, 2 and 4) with
chimeric or WT VLPs diluted in aluminum adjuvant. Serum samples were
collected at week 8 for PBNA.
For ED50 calculations, 40 SPF BALB/c mice (n= 8 per group) were vaccinated
by intraperitoneal injection with a single dose (0.3, 0.1, 0.033, 0.011, or 0.004 μg) of
each chimeric or WT VLP (serially diluted in aluminum adjuvant). The dose of
each VLP in the mixed WT VLP group was equal to that of the same VLP in the
single-type groups. Serum samples were taken 4 weeks after immunization, and the
seroconversion at each dose was calculated. The ED50 was reported in units of
micrograms of antigen per mouse, resulting in 50% seroconversion. The ED50
results were analyzed based on the dose-response curve using a Reed–Muench
model60.
To assess the immunogenicity of H58-33BC-52HI VLPs in non-human
primates, 20 cynomolgus macaques (Macaca Fascicularis)—with no detectable
neutralizing antibodies against infection of HPV33, -52 or -58—were divided into
five groups (n= 4). The first group was inoculated with H58-33BC-52HI VLP (5 μg
per dose); the other four groups were inoculated with HPV33 (5 μg per dose),
HPV52 (5 μg per dose), HPV58 (5 μg per dose) VLPs, and the mixed VLPs of
HPV33/52/58 (5 μg of HPV33, -52 and -58 per dose), respectively. All five groups
were immunized twice (months 0 and 2) by Intramuscular injection. Pre-immune
serum samples of each monkey were collected individually, and serum samples
were collected at 2-week intervals after immunization. The titers of HPV
neutralizing antibodies in these sera were detected by PBNA. All data for the
neutralization titers of per group analyzed by PBNA are plotted as the mean
with SD.
The sample size of animal studies were estimated according to our previous
studies61. All the mice used in this study were female and about 4–6 weeks old and
the age of mice were much the same in the same set experiments. The male and
female cynomolgus macaques were about 3 years old. All the animals were divided
randomly into a certain number groups. No blinding was done.
Cryo-EM and three-dimensional (3D) reconstruction. Purified mAb 4E5 Fab
fragments were incubated with HPV58, HPV58-33BC, or HPV58-33BC-52HI
VLPs at 37 °C for 2 h (molar ratios of 1:1.2 for all immune complexes). Small
aliquots (3 μL) of mixtures were deposited onto glow discharged holey carbon
Quantifoil Cu grids (R2/2, 200 mesh, Quantifoil Micro Tools), blotted with filter
paper for 6 s, and then vitrified by plunging into liquid ethane inside an FEI Mark
IV Vitrobot at 100% humidity. CryoEM micrographs were collected at 300 kV with
a FEI Tecnai F30 transmission electron microscope, equipped with Falcon II direct
electron detector at a defocus level from 1.5 to 3.5 µm evaluated using Gctf62. The
nominal magnification was set to 93,000 (pixel size= 1.128Å) with an electron
dose of 25 e−/Å2 at 1 s. Particles were manually picked using the e2boxer.py
program in EMAN2.163. After several rounds of reference-free 2D classifications
using Relion2.064, good particles were sorted for further 3D reconstruction and
refinement with AUTO3DEM65. Final map resolutions were determined by the
gold standard FSC curve between two-half maps with a cutoff of 0.366. HPV58
pentamer crystal structure were manually fitted using the program Chimera, and
further optimized into the corresponding maps using the “fit in map” command in
Chimera67.
Stereographic roadmap projections of HPV VLP-Fab complexes. The crystal
structures of HPV33, HPV58-33BC, HPV58-33BC-52HI were fitted into the cor-
responding cryoEM density map using the tool “fit in map” in Chimera, and were
then plotted onto stereographic spheres using RIVEM68 (Radial Interpretation of
Viral Electron Density Maps), where the polar angles θ and ϕ represent latitude
and longitude, respectively. The Fab density was projected as contour lines onto the
sphere, which is presented as a stereographic diagram.
Data availability:
The data supporting the findings of this study are available from the corresponding
authors upon reasonable request. Atomic coordinates and structure factors for the
HPV33, HPV52, H58-33BC and H58-33BC-52HI L1 pentamers have been
deposited in the Protein Data Bank (accession code 6IGE, 6IGF, 6IGD, and 6IGC).
The cryoEM density maps for HPV33:4E5, H58-33BC:4E5 and H58-33BC-
52HI:4E5 have been deposited in the Electron Microscopy Data Bank (accession
code EMD-9665, EMD-9666 and EMD-9667). A reporting summary for this
Article is available as a Supplementary Information file.
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